Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics

Date, Tushar; Nimbalkar, Vaishnavi; Kamat, Jyostna; Mittal, Anupama; Mahato, Ram I.; Chitkara, Deepak

doi:10.1016/j.jconrel.2017.12.016

Cited by 121 publications

(83 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be explained by the sustained release of the LPNs. 48 On the contrary, free I/D showed weaker fluorescence at 72 h than 24 h. At 72 h post administration, HA-I/D-LPNs showed 75.3 ± 3.3% fluorescence positivity, which is higher than I/D-LPNs (59.4 ± 2.2%, P < 0.05) and free I/ D (6.5 ± 0.6%, P < 0.01). Co-delivery of drug and DNA into the same tumor site is a key for achieving synergistic effect in the combined drug and gene therapy of cancer.…”

Section: In Vivo Transfection Efficiencymentioning

confidence: 77%

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

View full text Add to dashboard Cite

Background: The current approach for treating colorectal cancer favors the use of drug and gene combination therapy, and targeted nano-systems are gaining considerable attention for minimizing toxicity and improving the efficacy of anticancer treatment. The aim of this study was to develop ligand-modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers for targeted colorectal cancer combination therapy. Methods: Hyaluronic acid modified, irinotecan and gene co-loaded LPNs (HA-I/D-LPNs) were prepared using a solvent-evaporation method. Their average size, zeta potential, drug and gene loading capacity were characterized. The in vitro and in vivo gene transfection and anti-tumor ability of this nano-system were evaluated on colorectal cancer cells and mice bearing colorectal cancer model. Results: HA-I/D-LPNs had a size of 182.3 ± 5.1, over 80% drug encapsulation efficiency and over 90% of gene loading capacity. The peak plasma concentration (C max) and half-life (T 1/2) achieved from HA-I/D-LPNs were 41.31 ± 1.58 μg/mL and 12.56 ± 0.67 h. HA-I/ D-LPNs achieved the highest tumor growth inhibition efficacy and the most prominent transfection efficiency in vivo. Conclusion: HA-I/D-LPNs exhibited the most remarkable tumor inhibition efficacy and best gene transfection efficiency in the tumor, which could prove the effects of the drug and gene combination therapy.

show abstract

Section: In Vivo Transfection Efficiencymentioning

confidence: 77%

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Wang¹,

Zang²,

Wei³

et al. 2020

DDDT

View full text Add to dashboard Cite

show abstract

“…Also, co-loading of drugs with different physicochemical properties became possible. In other words, the polymeric core functions to encapsulate either water or oil-soluble drugs and to provide robust structures, whereas the external lipid coat offers the following advantages; (i) acts as a biocompatible shield, (ii) a template for surface modifications, (iii) a barrier preventing the fast leakage of water-soluble drugs (iv) possesses favourable stability in serum (longer circulation times) and (v) good cellular accumulation and targeting ability [33,[56][57][58][59][60][61]. In another study, it was observed that the incorporation of phospholipid into polymeric NPs could significantly enhance their intracellular accumulation [62].…”

Section: Alternative Coatingsmentioning

confidence: 99%

Limitations of Pegylated Nanocarriers: Unfavourable Physicochemical Properties, Biodistribution Patterns and Cellular and Subcellular Fates

Sebak

2018

Int J App Pharm

View full text Add to dashboard Cite

Assuming that polyethylene glycol (PEG)-conjugated or PEGylated nanocarriers always offer outstanding physicochemical properties and pharmacokinetics profiles when compared to non-PEGylated ones, is not always accurate. For example, drug-loaded PEGylated nanocarriers for the treatment of cancer will not magically escape the reticuloendothelial system (RES) sequestration and clearance, benefit from the enhanced permeability and retention (EPR) effect of the tumor leaky vasculature and preferentially accumulate in the target tissue or cells. This is too good to be true. In this review, several drawbacks of PEGylation will be discussed; for example, how PEGylation can give rise to unfavourable physicochemical characteristics (e. g. particle size and release patterns) and post in vivo administration limitations of the formulated nanocarriers (e. g. limited evasion of RES uptake, development of hypersensitivity reactions, reduced intracellular accumulation and interference with the subcellular processing of nanocarriers necessary to produce the intended pharmacological effect).This review aims at providing better understanding of the pros and cons of PEGylation, encouraging the use of PEGylation with caution, avoiding the assumption that PEGylation will provide all advantages needed to deliver nanocarriers to the target tissue and looking for alternatives to optimize nanocarriers’ utilization especially in the delivery of chemotherapeutic agents for the treatment of different types of cancer. This review comprises a summary of some of the reported literature between 2013 and 2018 using different search engines; PubMed, Science Direct and Google Scholar, and the keywords listed below.

show abstract

“…The concomitance of both polymer and lipid imparts the LPH structural integrity, serum stability, sustained drug release (from the polymer core) and high biocompatibility (from the lipid shell) [21]. Finally, rapid opsonization induced by the lipidic shell resulting in rapid uptake of the particles by the mononuclear phagocyte system (MPS) in the liver and spleen has been previously proven [26,27].…”

Section: Introductionmentioning

confidence: 99%

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

et al. 2020

View full text Add to dashboard Cite

A platform capable of specifically delivering an antiviral drug to the liver infected with hepatitis B is a major concern in hepatology. Vaccination has had a major effect on decreasing the emerging numbers of new cases of infection. However, the total elimination of the hepatitis B virus from the body requires prolonged therapy. In this work, we aimed to target the liver macrophages with lipid polymer hybrid nanoparticles (LPH), combining the merit of polymeric nanoparticles and lipid vesicles. The hydrophilic antiviral drug, entecavir (E), loaded LPH nanoparticles were optimized and physicochemically characterized. A modulated lipidic corona, as well as, an additional coat with vitamin E were used to extend the drug release enhance the macrophage uptake. The selected vitamin E coated LPH nanoparticles enriched with lecithin-glyceryl monostearate lipid shell exhibited high entrapment for E (80.47%), a size � 200 nm for liver passive targeting, extended release over one week, proven serum stability, retained stability after refrigeration storage for 6 months. Upon macrophage uptake in vitro assessment, the presented formulation displayed promising traits, enhancing the cellular retention in J774 macrophages cells. In vivo and antiviral activity futuristic studies would help in the potential application of the ELPH in hepatitis B control.

show abstract

Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics

Cited by 121 publications

References 134 publications

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

<p>Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer</p>

Limitations of Pegylated Nanocarriers: Unfavourable Physicochemical Properties, Biodistribution Patterns and Cellular and Subcellular Fates

An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect

Contact Info

Product

Resources

About